Adverse patent ruling could cost Genentech millions

PAUL ELIAS Associated Press

SAN FRANCISCO - Federal regulators rejected a valuable Genentech Inc. patent that protects how it makes some biotechnology drugs, the company said Wednesday. While the U.S Patent and Trademark Office ruling could cost the company millions of dollars in royalty payments, the South San Francisco-based company said the patent would remain valid while it pursues appeals at the USPTO and the courts. The appeals process could last longer than two years.

Full story.